Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Aug 26, 2014; 6(8): 728-743
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.728
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.728
Prehypertension: Underlying pathology and therapeutic options
Sulayma Albarwani, Sultan Al-Siyabi, Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat 123, Oman
Musbah O Tanira, Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat 123, Oman
Author contributions: Albarwani S, Al-Siyabi S and Tanira MO solely contributed to this paper.
Correspondence to: Dr. Sulayma Albarwani, Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, P.O.Box 35, Muscat 123, Oman. salbarwani@squ.edu.om
Telephone: +968-24141108 Fax: +968-24143514
Received: December 17, 2013
Revised: June 8, 2014
Accepted: June 14, 2014
Published online: August 26, 2014
Processing time: 273 Days and 23.5 Hours
Revised: June 8, 2014
Accepted: June 14, 2014
Published online: August 26, 2014
Processing time: 273 Days and 23.5 Hours
Core Tip
Core tip: There is a current debate over the ideal means of intervening in prehypertension. Since it is the cardiovascular risk that constitute the basis for intervention in both prehypertension and hypertension, the review discusses the following points, that: (1) categorizing blood pressure levels is based on mere 20 mmHg brackets; hence this doctrine may be re-visited to include other cardiovascular risk factors to categorize patients regardless of their blood pressure level; (2) investigating the therapeutic potential of intervening in all pathophysiological processes associated with prehypertension; and (3) ascertaining the therapeutic value of the “Polypill” in prehypertensives as means of primary prevention.